Positive results in the PRO 140 clinical trials should mean good news for investors, CytoDyn President Nader Pourhassan said in an interview CytoDyn is currently undervalued but the effectiveness and practical appeal of PRO 140 should contribute to a turning point in stock prices PRO 140, a single agent therapy, is proving highly effective in […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.